Roland Geisberger
Overview
Explore the profile of Roland Geisberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
656
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parigger T, Gassner F, Drothler S, Scherhaufl C, Hodlmoser A, Schultheis L, et al.
Technol Cancer Res Treat
. 2024 May;
23:15330338241252706.
PMID: 38766867
In this study, stool samples were evaluated for tumor mutation analysis a targeted next generation sequencing (NGS) approach in a small patient cohort suffering from localized rectal cancer. Colorectal cancer...
2.
Parigger T, Drothler S, Scherhaufl C, Gassner F, Schubert M, Steiner M, et al.
Acta Haematol
. 2024 Feb;
147(5):604-611.
PMID: 38402867
Introduction: Targeting the B-cell receptor pathway via ibrutinib, a specific inhibitor of Bruton's tyrosine kinase, has shown marked clinical efficacy in treatment of patients with chronic lymphocytic leukemia (CLL), thus...
3.
Hoeger B, Nadolni W, Hampe S, Hoelting K, Fraticelli M, Zaborsky N, et al.
Function (Oxf)
. 2023 Oct;
4(6):zqad053.
PMID: 37786778
Cyclooxygenase-2 (COX-2) is a key regulator of inflammation. High constitutive expression enhances survival and proliferation of cancer cells, and adversely impacts antitumor immunity. The expression of is modulated by various...
4.
Vaisband M, Schubert M, Gassner F, Geisberger R, Greil R, Zaborsky N, et al.
BMC Bioinformatics
. 2023 Apr;
24(1):158.
PMID: 37081386
Accurate somatic variant calling from next-generation sequencing data is one most important tasks in personalised cancer therapy. The sophistication of the available technologies is ever-increasing, yet, manual candidate refinement is...
5.
Akimova E, Gassner F, Greil R, Zaborsky N, Geisberger R
Int J Mol Sci
. 2022 Feb;
23(3).
PMID: 35163016
Chronic lymphocytic leukemia (CLL) is a very common and mostly incurable B-cell malignancy. Recent studies revealed high interpatient mutational heterogeneity and worsened therapy response and survival of patients with complex...
6.
Steiner M, Gassner F, Parigger T, Neureiter D, Egle A, Geisberger R, et al.
Int J Mol Sci
. 2021 Sep;
22(17).
PMID: 34502317
Chronic lymphocytic leukemia (CLL) is considered a clonal B cell malignancy. Sporadically, CLL cases with multiple productive heavy and light-chain rearrangements were detected, thus leading to a bi- or oligoclonal...
7.
Haslauer T, Greil R, Zaborsky N, Geisberger R
Int J Mol Sci
. 2021 Aug;
22(16).
PMID: 34445701
Chimeric antigen receptor (CAR) T-cells (CAR T-cells) are a promising therapeutic approach in treating hematological malignancies. CAR T-cells represent engineered autologous T-cells, expressing a synthetic CAR, targeting tumor-associated antigens (TAAs)...
8.
Parigger T, Gassner F, Scherhaufl C, Bakar A, Hopner J, Hodlmoser A, et al.
Int J Mol Sci
. 2021 Jul;
22(13).
PMID: 34206229
The reinvigoration of anti-cancer immunity by immune checkpoint therapies has greatly improved cancer treatment. In chronic lymphocytic leukemia (CLL), patients as well as in the Tcl1 mouse model for CLL,...
9.
Schubert M, Gassner F, Huemer M, Hopner J, Akimova E, Steiner M, et al.
Cancers (Basel)
. 2021 Jun;
13(11).
PMID: 34073525
Adaptive somatic mutations conferring treatment resistance and accelerated disease progression is still a major problem in cancer therapy. Additionally in CLL, patients receiving novel, efficient drugs frequently become treatment refractory...
10.
Akimova E, Gassner F, Schubert M, Rebhandl S, Arzt C, Rauscher S, et al.
Nucleic Acids Res
. 2021 Feb;
49(5):2598-2608.
PMID: 33591315
Aberrant end joining of DNA double strand breaks leads to chromosomal rearrangements and to insertion of nuclear or mitochondrial DNA into breakpoints, which is commonly observed in cancer cells and...